Waddell & Reed Increases Stake In Wynn Resorts (WYNN) to 11.3% Nov 6, 2009 09:58AM

In a 13G filing on Wynn Resorts (Nasdaq: WYNN) mutual fund Waddell & Reed disclosed an 11.3%, or 14,293,685 share, stake in the casino operator as of October 31, 2009.

The mutual fund operator has been steadily increasing their stake from the 11,531,760 shares held at September 30, 2009 and 6,416,580 shares held at the quarter ended June 30, 2009.


Leon Cooperman Raises Stake In Given Imaging (GIVN) Above 5% Nov 5, 2009 08:43AM

In a 13G filing on Given Imaging Ltd. (Nasdaq: GIVN), Leon Cooperman disclosed a 5.4%, or 1,588,409 share, stake in the company. A 13G indicates a passive investment over 5%.

Cooperman held 978,709 at the quarter ended June 30, 2009.


Mandel's Lone Pine Capital Show New 5.5% Stake in MSCI (MXB) Oct 13, 2009 05:21PM

In a 13G filing, MSCI, Inc. (NYSE: MXB), Stephen Mandel's Lone Pine Capital hedge fund disclosed a 5.5%, or 5,476,525 share, stake in the company. The firm did not show a stake in MXB at the quarter ended June 30, 2009. A 13G indicates a 'passive investment' above 5%.

MSCI Inc. provides investment decision support tools.


Griffin's Citadel Shows 5.2% Stake In Comtech Telecommunications (CMTL) Sep 24, 2009 09:27AM

In a 13G filing on Comtech Telecommunications (Nasdaq: CMTL), Ken Griffin's Citadel LP hedge fund disclosed a 5.2%, or 1,544,411 share, stake in the company. The firm held just 3,607 shares at the quarter ended June 30, 2009. A 13G indicates a 'passive investment' above 5%.

Comtech Telecommunications Corp. engages in the design, development, production, and marketing of products, systems, and services for advanced communications solutions in the United States and internationally.


Cohen's SAC Capital Accumulates Nearly 5M Shares of Salix Pharmaceuticals (SLXP) Sep 23, 2009 04:34PM

In a 13G filing on Salix Pharmaceuticals Ltd. (Nasdaq: SLXP), Steven Cohen's SAC Capital hedge fund disclosed a 9.9%, or 4,778,380 share, stake in the company. The firm held just 107,300 shares of SLXP at the quarter ended June 30, 2009. A 13G indicates a 'passive investment' above 5%.

On Sept 14, Salix announced the successful outcome of two Phase 3, randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).


Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php


More 13Gs

View Older Stories

Sep 21, 2009 07:26AM SAC Capital Boosts Stake In Incyte Corporation (INCY) to 5.3%
View Older Stories